Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy

BACKGROUND: Vascular endothelial growth factor (VEGF) is a critical regulator of malignant pleural effusion (MPE) in non-small-cell lung cancer (NSCLC). Bevacizumab (BEV) and apatinib (APA) are novel VEGF blockers that inhibit lung cancer cell proliferation and the development of pleural effusion. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Zhangqiang, Deng, Xiangyu, He, Wenfeng, Yang, Qian, Ni, Laichao, Dehghan Shasaltaneh, Marzieh, Maghsoudloo, Mazaher, Yang, Gang, Wu, Jingbo, Imani, Saber, Wen, Qinglian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103356/
https://www.ncbi.nlm.nih.gov/pubmed/35543207
http://dx.doi.org/10.1080/07853890.2022.2071977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103356/
https://www.ncbi.nlm.nih.gov/pubmed/35543207
http://dx.doi.org/10.1080/07853890.2022.2071977

Ejemplares similares